Japan Lifeline Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Dividend History 2Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥53 | +26.2% |
| 2024 | ¥42 | +10.5% |
| 2023 | ¥38 | 0.0% |
| 2022 | ¥38 | -22.4% |
| 2021 | ¥49 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥51,469M | ¥51,750M | ¥51,384M | ¥56,610M |
| Gross Profit | ¥28,835M | ¥29,895M | ¥30,986M | ¥34,191M |
| Operating Income | ¥9,981M | ¥10,844M | ¥10,899M | ¥12,336M |
| Pretax Income | ¥10,117M | ¥9,823M | ¥10,601M | ¥12,060M |
| Net Income | ¥7,484M | ¥6,891M | ¥7,515M | ¥9,317M |
| EPS | ¥93.13 | ¥88.22 | ¥98.73 | ¥131.43 |
| Operating Margin | 19.39% | 20.95% | 21.21% | 21.79% |
| Balance Sheet | ||||
| Total Assets | ¥73,197M | ¥74,641M | ¥73,509M | ¥75,123M |
| Total Equity | ¥54,567M | ¥56,196M | ¥58,101M | ¥59,913M |
| Total Liabilities | ¥18,630M | ¥18,445M | ¥15,408M | ¥15,210M |
| Cash | ¥16,058M | ¥18,357M | ¥12,669M | ¥11,014M |
| Interest-bearing Debt | ¥8,141M | ¥6,685M | ¥4,489M | ¥3,833M |
| Equity Ratio | 74.55% | 75.29% | 79.04% | 79.75% |
| D/E Ratio | 0.15 | 0.12 | 0.08 | 0.06 |
| Cash Flow | ||||
| Operating CF | ¥10,246M | ¥11,201M | ¥6,918M | ¥9,113M |
| Investing CF | -¥1,131M | -¥2,461M | -¥4,056M | -¥1,801M |
| Financing CF | -¥6,804M | -¥6,476M | -¥8,553M | -¥9,040M |
| Free CF | ¥8,388M | ¥9,472M | ¥4,578M | ¥7,514M |
| Efficiency | ||||
| ROE | 13.72% | 12.26% | 12.93% | 15.55% |
| ROA | 10.22% | 9.23% | 10.22% | 12.40% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 7575
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,680
Rating Score: - (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Japan Lifeline Co., Ltd., a medical device company, engages in manufacturing and sale of medical device in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, disposable ECG recorder, and venous vascular closure system. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts, as well as embolic coil deploying systems. In addition, the company offers gastrointestinal intervention products, including cholangioscope, biliary tube stent, papillary balloon dilatation catheter, self-expandable duodenal and colonic stent, endoscopic guidewire, and radiofrequency ablation systems; structural heart disease intervention products, such as radiofrequency wires and atrial septal defect closure devices; and aspiration catheter neurovascular intervention product. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.